FDA
-
-
-
-
-
-
-
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
-
-
-
-
-
-
-
Vivani Medical (VANI) Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
-
-
-
-
-
-
-
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
-
-
-
-
-
-
-
Vivani Medical to Present at TIDES Conference 2024
-
-
-
-
-
-
-
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
-
-
-
-
-
-
-
Vivani Medical's (VANI) Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
-
-
-
-
-
-
-
Vivani Medical (VANI) Files for Proposed IPO of its Subsidiary Cortigent
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

